Menu
Back to Journals » Breast Cancer: Targets and Therapy
Breast Cancer: Targets and Therapy
- View all (224)
- Volume 10, 2018 (14)
- Volume 9, 2017 (64)
- Volume 8, 2016 (26)
- Volume 7, 2015 (36)
- Volume 6, 2014 (20)
- Volume 5, 2013 (13)
- Volume 4, 2012 (22)
- Volume 3, 2011 (16)
- Volume 2, 2010 (9)
- Volume 1, 2009 (4)
Journal Articles:
- 224 records -
Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer
Franco YL, Vaidya TR, Ait-Oudhia S
Breast Cancer: Targets and Therapy 2018, 10:131-141
Published Date: 11 September 2018
Single-day HER2neu amplification assessment using chip-based digital PCR in formalin-fixed paraffin-embedded breast carcinoma tissue
Shah PS, Murarka S, Joshi A, Mehta B, Parmar V, Shah N, Patel K, Sands J
Breast Cancer: Targets and Therapy 2018, 10:121-129
Published Date: 23 July 2018
Evaluation of the SnapChat mobile social networking application for breast cancer awareness among Saudi students in the Dammam Region of the Kingdom of Saudi Arabia
Alanzi TM, Alobrah A, Alhumaidi R, Aloraifi S
Breast Cancer: Targets and Therapy 2018, 10:113-119
Published Date: 12 July 2018
Complexes formed by mutant p53 and their roles in breast cancer
Bellazzo A, Sicari D, Valentino E, Del Sal G, Collavin L
Breast Cancer: Targets and Therapy 2018, 10:101-112
Published Date: 18 June 2018
Mechanism of metastasis suppression by luteolin in breast cancer
Cook MT
Breast Cancer: Targets and Therapy 2018, 10:89-100
Published Date: 12 June 2018
Impact of semaphorin expression on prognostic characteristics in breast cancer
Butti R, Kumar TVS, Nimma R, Kundu GC
Breast Cancer: Targets and Therapy 2018, 10:79-88
Published Date: 31 May 2018
Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2– metastatic breast cancer
Forsythe A, Chandiwana D, Barth J, Thabane M, Baeck J, Tremblay G
Breast Cancer: Targets and Therapy 2018, 10:69-78
Published Date: 4 May 2018
A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts
Liang Y, Mafuvadze B, Besch-Williford C, Hyder SM
Breast Cancer: Targets and Therapy 2018, 10:53-67
Published Date: 22 March 2018
Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date [Corrigendum]
Criscitiello C, Viale G, Curigliano G, Goldhirsch A
Breast Cancer: Targets and Therapy 2018, 10:51-52
Published Date: 16 March 2018
Spotlight on triptorelin in the treatment of premenopausal women with early-stage breast cancer
Venturelli M, Guaitoli G, Omarini C, Moscetti L
Breast Cancer: Targets and Therapy 2018, 10:39-49
Published Date: 6 March 2018
Choosing wisely after publication of level I evidence in breast cancer radiotherapy
Niska JR, Keole SR, Pockaj BA, Halyard MY, Patel SH, Northfelt DW, Gray RJ, Wasif N, Vargas CE, Wong WW
Breast Cancer: Targets and Therapy 2018, 10:31-37
Published Date: 9 February 2018
Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date
Criscitiello C, Viale G, Curigliano G, Goldhirsch A
Breast Cancer: Targets and Therapy 2018, 10:23-29
Published Date: 30 January 2018
One-step nucleic acid amplification: the possible value in assessing sentinel lymph node metastasis during mastectomy
Hunter-Smith AE, Rayter Z
Breast Cancer: Targets and Therapy 2018, 10:13-21
Published Date: 25 January 2018
The effects of black cohosh on the regulation of estrogen receptor (ERα) and progesterone receptor (PR) in breast cancer cells
Szmyd M, Lloyd V, Hallman K, Aleck K, Mladenovik V, McKee C, Morse M, Bedgood T, Dinda S
Breast Cancer: Targets and Therapy 2018, 10:1-11
Published Date: 18 January 2018
Pleomorphic lobular carcinoma: is it more similar to a classic lobular cancer or to a high-grade ductal cancer?
Costarelli L, Campagna D, Ascarelli A, Cavaliere F, Colavito MH, Ponzani T, Broglia L, La Pinta M, Manna E, Fortunato L
Breast Cancer: Targets and Therapy 2017, 9:581-586
Published Date: 8 December 2017
Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2− metastatic breast cancer: a focus on ribociclib
Edessa D, Sisay M
Breast Cancer: Targets and Therapy 2017, 9:567-579
Published Date: 6 December 2017
Effect of statins on breast cancer recurrence and mortality: a review
Van Wyhe RD, Rahal OM, Woodward WA
Breast Cancer: Targets and Therapy 2017, 9:559-565
Published Date: 1 December 2017
Prevention and treatment of acute and chronic radiodermatitis
Seité S, Bensadoun RJ, Mazer JM
Breast Cancer: Targets and Therapy 2017, 9:551-557
Published Date: 2 November 2017
Profiling of gene expression regulated by 17β-estradiol and tamoxifen in estrogen receptor-positive and estrogen receptor-negative human breast cancer cell lines
Rangel N, Villegas VE, Rondón-Lagos M
Breast Cancer: Targets and Therapy 2017, 9:537-550
Published Date: 20 September 2017
Increased risk of breast cancer in neurofibromatosis type 1: current insights
Howell SJ, Hockenhull K, Salih Z, Evans DG
Breast Cancer: Targets and Therapy 2017, 9:531-536
Published Date: 21 August 2017
Oncological safety and cosmetic outcomes in oncoplastic breast conservation surgery, a review of the best level of evidence literature
Campbell EJ, Romics L
Breast Cancer: Targets and Therapy 2017, 9:521-530
Published Date: 4 August 2017
Discordance of the estrogen receptor and HER-2/neu in breast cancer from primary lesion to first and second metastatic site
Lower EE, Khan S, Kennedy D, Baughman RP
Breast Cancer: Targets and Therapy 2017, 9:515-520
Published Date: 2 August 2017
The ABC7 regimen: a new approach to metastatic breast cancer using seven common drugs to inhibit epithelial-to-mesenchymal transition and augment capecitabine efficacy
Kast RE, Skuli N, Cos S, Karpel-Massler G, Shiozawa Y, Goshen R, Halatsch ME
Breast Cancer: Targets and Therapy 2017, 9:495-514
Published Date: 11 July 2017
Cholesterol biosynthesis inhibitor RO 48-8071 reduces progesterone receptor expression and inhibits progestin-dependent stem cell-like cell growth in hormone-dependent human breast cancer cells
Liang Y, Goyette S, Hyder SM
Breast Cancer: Targets and Therapy 2017, 9:487-494
Published Date: 7 July 2017
A systematic literature review exploring the prevalence of post-traumatic stress disorder and the role played by stress and traumatic stress in breast cancer diagnosis and trajectory
Arnaboldi P, Riva S, Crico C, Pravettoni G
Breast Cancer: Targets and Therapy 2017, 9:473-485
Published Date: 6 July 2017
Comparative diagnostic accuracy of 18F-FDG PET/CT for breast cancer recurrence
Piva R, Ticconi F, Ceriani V, Scalorbi F, Fiz F, Capitanio S, Bauckneht M, Cittadini G, Sambuceti G, Morbelli S
Breast Cancer: Targets and Therapy 2017, 9:461-471
Published Date: 4 July 2017
Structure-based virtual screening and molecular docking for the identification of potential multi-targeted inhibitors against breast cancer
Yousuf Z, Iman K, Iftikhar N, Mirza MU
Breast Cancer: Targets and Therapy 2017, 9:447-459
Published Date: 14 June 2017
An effective deep-inspiration breath-hold radiotherapy technique for left-breast cancer: impact of post-mastectomy treatment, nodal coverage, and dose schedule on organs at risk
Rice L, Goldsmith C, Green MML, Cleator S, Price PM
Breast Cancer: Targets and Therapy 2017, 9:437-446
Published Date: 14 June 2017
High glucose levels promote the proliferation of breast cancer cells through GTPases
Hou Y, Zhou M, Xie J, Chao P, Feng Q, Wu J
Breast Cancer: Targets and Therapy 2017, 9:429-436
Published Date: 13 June 2017
Loss of constitutive ABCB1 expression in breast cancer associated with worse prognosis
Delou JM, Vignal GM, Índio-do-Brasil V, Accioly MT, da Silva TS, Piranda DN, Sobral-Leite M, Carvalho MA, Capella MA, Vianna-Jorge R
Breast Cancer: Targets and Therapy 2017, 9:415-428
Published Date: 10 June 2017
Younger age is an independent predictor of worse prognosis among Lebanese nonmetastatic breast cancer patients: analysis of a prospective cohort
El Chediak A, Alameddine RS, Hakim A, Hilal L, Abdel Massih S, Hamieh L, Mukherji D, Temraz S, Charafeddine M, Shamseddine A
Breast Cancer: Targets and Therapy 2017, 9:407-414
Published Date: 10 June 2017
Single nucleotide polymorphisms and unacceptable late toxicity in breast cancer adjuvant radiotherapy: a case report
Lazzari G, Natalicchio MI, Terlizzi A, Perri F, Silvano G
Breast Cancer: Targets and Therapy 2017, 9:401-406
Published Date: 29 May 2017
Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer
McVeigh TP, Kerin MJ
Breast Cancer: Targets and Therapy 2017, 9:393-400
Published Date: 29 May 2017
SR-B1-targeted nanodelivery of anti-cancer agents: a promising new approach to treat triple-negative breast cancer
Johnson R, Sabnis N, Sun X, Ahluwalia R, Lacko AG
Breast Cancer: Targets and Therapy 2017, 9:383-392
Published Date: 2 June 2017
Changes in pulmonary function tests in breast carcinoma patients treated with locoregional post-mastectomy radiotherapy: results of a pilot study
AlSaeed EF, Balaraj FK, Tunio MA
Breast Cancer: Targets and Therapy 2017, 9:375-381
Published Date: 29 May 2017
The regulation of steroid receptors by epigallocatechin-3-gallate in breast cancer cells
Hallman K, Aleck K, Quigley M, Dwyer B, Lloyd V, Szmyd M, Dinda S
Breast Cancer: Targets and Therapy 2017, 9:365-373
Published Date: 24 May 2017
Effect of reduced dietary fat on estradiol, adiponectin, and IGF-1 levels in postmenopausal women with breast cancer
Murillo-Ortiz B, Martínez-Garza S, Cárdenas Landeros V, Cano Velázquez G, Suárez Garcia D
Breast Cancer: Targets and Therapy 2017, 9:359-364
Published Date: 23 May 2017
Natural and synthetic progestins enrich cancer stem cell-like cells in hormone-responsive human breast cancer cell populations in vitro
Goyette S, Liang Y, Mafuvadze B, Cook MT, Munir M, Hyder SM
Breast Cancer: Targets and Therapy 2017, 9:347-357
Published Date: 19 May 2017
Invasive lobular carcinoma of the male breast – a systematic review with an illustrative case study
Senger JL, Adams SJ, Kanthan R
Breast Cancer: Targets and Therapy 2017, 9:337-345
Published Date: 17 May 2017
Current perspectives on CHEK2 mutations in breast cancer
Apostolou P, Papasotiriou I
Breast Cancer: Targets and Therapy 2017, 9:331-335
Published Date: 12 May 2017
Imprint cytology versus frozen section analysis for intraoperative assessment of sentinel lymph node in breast cancer
Petropoulou T, Kapoula A, Mastoraki A, Politi A, Spanidou-Karvouni E, Psychogios I, Vassiliou I, Arkadopoulos N
Breast Cancer: Targets and Therapy 2017, 9:325-330
Published Date: 5 May 2017
Acute radiation dermatitis in breast cancer patients: challenges and solutions
Kole AJ, Kole L, Moran MS
Breast Cancer: Targets and Therapy 2017, 9:313-323
Published Date: 5 May 2017
Prognostic value of histone chaperone FACT subunits expression in breast cancer
Attwood K, Fleyshman D, Prendergast L, Paszkiewicz G, Omilian AR, Bshara W, Gurova K
Breast Cancer: Targets and Therapy 2017, 9:301-311
Published Date: 3 May 2017
Metaplastic breast carcinoma with upper limb gangrene
Rajan R, Abdullah N, Abdullah NMA, Mohd Kassim AY
Breast Cancer: Targets and Therapy 2017, 9:297-299
Published Date: 2 May 2017
Improved immediate breast reconstruction as a result of oncoplastic multidisciplinary meeting
El Gammal MM, Lim M, Uppal R, Sainsbury R
Breast Cancer: Targets and Therapy 2017, 9:293-296
Published Date: 28 April 2017
Breast cancer and amyloid bodies: is there a role for amyloidosis in cancer-cell dormancy?
Mizejewski GJ
Breast Cancer: Targets and Therapy 2017, 9:287-291
Published Date: 26 April 2017
Lymphoscintigraphy detecting alterations of upper limb lymphatic flow following early sentinel lymph node biopsy in breast cancer
Sarri AJ, Tinois da Silva E, Vieira RAC, Koga KH, Cação PHM, Sarri VC, Moriguchi SM
Breast Cancer: Targets and Therapy 2017, 9:279-285
Published Date: 19 April 2017
Mentha arvensis (Linn.)-mediated green silver nanoparticles trigger caspase 9-dependent cell death in MCF7 and MDA-MB-231 cells
Banerjee PP, Bandyopadhyay A, Harsha SN, Policegoudra RS, Bhattacharya S, Karak N, Chattopadhyay A
Breast Cancer: Targets and Therapy 2017, 9:265-278
Published Date: 18 April 2017
Intraoperative radiation therapy for breast cancer patients: current perspectives
Dutta SW, Showalter SL, Showalter TN, Libby B, Trifiletti DM
Breast Cancer: Targets and Therapy 2017, 9:257-263
Published Date: 18 April 2017
Effects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients
Charoenchokthavee W, Areepium N, Panomvana D, Sriuranpong V
Breast Cancer: Targets and Therapy 2017, 9:249-256
Published Date: 15 April 2017
Granular cell tumor in breast: a case report
Castillo Lara M, Martínez Herrera A, Torrejón Cardoso R, Lubián López DM
Breast Cancer: Targets and Therapy 2017, 9:245-248
Published Date: 11 April 2017
Tumescent mastectomy: the current indications and operative tips and tricks
Khater A, Mazy A, Gad M, Taha Abd Eldayem O, Hegazy M
Breast Cancer: Targets and Therapy 2017, 9:237-243
Published Date: 30 March 2017
The role of the chemokine receptor XCR1 in breast cancer cells
Yang XL, Qi LG, Lin FJ, Ou ZL
Breast Cancer: Targets and Therapy 2017, 9:227-236
Published Date: 29 March 2017
Economic analysis of the breast cancer screening program used by the UK NHS: should the program be maintained?
Morton R, Sayma M, Sura MS
Breast Cancer: Targets and Therapy 2017, 9:217-225
Published Date: 24 March 2017
Breast cancer in patients with Li–Fraumeni syndrome – a case-series study and review of literature
Nandikolla AG, Venugopal S, Anampa J
Breast Cancer: Targets and Therapy 2017, 9:207-215
Published Date: 23 March 2017
Validation of Health Behavior and Stages of Change Questionnaire
Gonzalez-Ramirez LP, De la Roca-Chiapas JM, Colunga-Rodriguez C, Preciado-Serrano MDL, Daneri-Navarro A, Pedroza-Cabrera FJ, Martinez-Arriaga RJ
Breast Cancer: Targets and Therapy 2017, 9:199-205
Published Date: 22 March 2017
Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response
Jernström S, Hongisto V, Leivonen SK, Due EU, Tadele DS, Edgren H, Kallioniemi O, Perälä M, Mælandsmo GM, Sahlberg KK
Breast Cancer: Targets and Therapy 2017, 9:185-198
Published Date: 21 March 2017
Intensity-modulated radiation therapy for early-stage breast cancer: is it ready for prime time?
Chan TY, Tan PW, Tang JI
Breast Cancer: Targets and Therapy 2017, 9:177-183
Published Date: 20 March 2017
Preexposure of MCF-7 breast cancer cell line to dexamethasone alters the cytotoxic effect of paclitaxel but not 5-fluorouracil or epirubicin chemotherapy
Buxant F, Kindt N, Noël JC, Laurent G, Saussez S
Breast Cancer: Targets and Therapy 2017, 9:171-175
Published Date: 16 March 2017
Knowledge, attitudes and behaviors of primary health care nurses and midwives in breast cancer early diagnosis applications
Bulut A, Bulut A
Breast Cancer: Targets and Therapy 2017, 9:163-169
Published Date: 13 March 2017
The effects of turmeric (curcumin) on tumor suppressor protein (p53) and estrogen receptor (ERα) in breast cancer cells
Hallman K, Aleck K, Dwyer B, Lloyd V, Quigley M, Sitto N, Siebert AE, Dinda S
Breast Cancer: Targets and Therapy 2017, 9:153-161
Published Date: 10 March 2017
Mastectomy skin flap necrosis: challenges and solutions
Robertson SA, Jeevaratnam JA, Agrawal A, Cutress RI
Breast Cancer: Targets and Therapy 2017, 9:141-152
Published Date: 13 March 2017
Silicone-induced granuloma of breast implant capsule (SIGBIC): similarities and differences with anaplastic large cell lymphoma (ALCL) and their differential diagnosis
Fleury EF, Rêgo MM, Ramalho LC, Ayres VJ, Seleti RO, Ferreira CA, Roveda Jr D
Breast Cancer: Targets and Therapy 2017, 9:133-140
Published Date: 10 March 2017
Recent insights into cigarette smoking as a lifestyle risk factor for breast cancer
Kispert S, McHowat J
Breast Cancer: Targets and Therapy 2017, 9:127-132
Published Date: 7 March 2017
Intensity modulated radiation therapy for breast cancer: current perspectives
Buwenge M, Cammelli S, Ammendolia I, Tolento G, Zamagni A, Arcelli A, Macchia G, Deodato F, Cilla S, Morganti AG
Breast Cancer: Targets and Therapy 2017, 9:121-126
Published Date: 6 March 2017
CYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study
Wickramage I, Tennekoon KH, Ariyaratne MAY, Hewage AS, Sundralingam T
Breast Cancer: Targets and Therapy 2017, 9:111-120
Published Date: 6 March 2017
An exploratory study of host polymorphisms in genes that clinically characterize breast cancer tumors and pretreatment cognitive performance in breast cancer survivors
Koleck TA, Bender CM, Clark BZ, Ryan CM, Ghotkar P, Brufsky A, McAuliffe PF, Rastogi P, Sereika SM, Conley YP
Breast Cancer: Targets and Therapy 2017, 9:95-110
Published Date: 3 March 2017
Alternative therapies for metastatic breast cancer: multimodal approach targeting tumor cell heterogeneity
Sambi M, Haq S, Samuel V, Qorri B, Haxho F, Hill K, Harless W, Szewczuk MR
Breast Cancer: Targets and Therapy 2017, 9:85-93
Published Date: 28 February 2017
Ulva lactuca polysaccharides prevent Wistar rat breast carcinogenesis through the augmentation of apoptosis, enhancement of antioxidant defense system, and suppression of inflammation
Abd-Ellatef GF, Ahmed OM, Abdel-Reheim ES, Abdel-Hamid AZ
Breast Cancer: Targets and Therapy 2017, 9:67-83
Published Date: 27 February 2017
Nanomolar concentration of blood-soluble drag-reducing polymer inhibits experimental metastasis of human breast cancer cells
Ding Z, Joy M, Kameneva MV, Roy P
Breast Cancer: Targets and Therapy 2017, 9:61-65
Published Date: 24 February 2017
Comment on "Gastric and colon metastasis from breast cancer: case report, review of the literature, and possible underlying mechanisms’’
Talebi Bezmin Abadi A
Breast Cancer: Targets and Therapy 2017, 9:59-60
Published Date: 24 February 2017
The predictors of poor quality of life in a sample of Saudi women with breast cancer
Ahmed AE, Alharbi AG, Alsadhan MA, Almuzaini AS, Almuzaini HS, Ali YZ, Jazieh AR
Breast Cancer: Targets and Therapy 2017, 9:51-58
Published Date: 9 February 2017
Reduction in breast cancer susceptibility due to XbaI gene polymorphism of alpha estrogen receptor gene in Jordanians
Atoum MF, Alzoughool F
Breast Cancer: Targets and Therapy 2017, 9:45-49
Published Date: 24 January 2017
Docetaxel-associated myalgia–arthralgia syndrome in patients with breast cancer
Seguin C, Kovacevich N, Voutsadakis IA
Breast Cancer: Targets and Therapy 2017, 9:39-44
Published Date: 23 January 2017
Breast cancer in Mongolia: an increasingly important health policy issue
Demchig D, Mello-Thoms C, Brennan PC
Breast Cancer: Targets and Therapy 2017, 9:29-38
Published Date: 20 January 2017
Association between telomere length and CYP19 TTTA repetition polymorphism in healthy and breast cancer-diagnosed women
Murillo-Ortiz B, Martínez-Garza S, Suárez García D, Castillo Valenzuela RDC, García Regalado JF, Cano Velázquez G
Breast Cancer: Targets and Therapy 2017, 9:21-27
Published Date: 13 January 2017
Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells
Cook MT, Liang Y, Besch-Williford C, Hyder SM
Breast Cancer: Targets and Therapy 2017, 9:9-19
Published Date: 23 December 2016
Gastric and colon metastasis from breast cancer: case report, review of the literature, and possible underlying mechanisms
Villa Guzmán JC, Espinosa J, Cervera R, Delgado M, Patón R, Cordero García JM
Breast Cancer: Targets and Therapy 2017, 9:1-7
Published Date: 23 December 2016
Expression and functionality of TRPV1 in breast cancer cells
Weber LV, Al-Refae K, Wölk G, Bonatz G, Altmüller J, Becker C, Gisselmann G, Hatt H
Breast Cancer: Targets and Therapy 2016, 8:243-252
Published Date: 13 December 2016
Role of natural herbs and phytochemicals to minimize tumor and economic burden in breast cancer treatment
Shoaib M, Ahmed SA
Breast Cancer: Targets and Therapy 2016, 8:241-242
Published Date: 7 December 2016
Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study
Puhalla S, Wilks S, Brufsky AM, O'Shaughnessy J, Schwartzberg LS, Berrak E, Song J, Vahdat L
Breast Cancer: Targets and Therapy 2016, 8:231-239
Published Date: 7 December 2016
HMMR antisense RNA 1, a novel long noncoding RNA, regulates the progression of basal-like breast cancer cells
Liu W, Ma J, Cheng Y, Zhang H, Luo W, Zhang H
Breast Cancer: Targets and Therapy 2016, 8:223-229
Published Date: 24 November 2016
Tumor suppressor ING4 inhibits estrogen receptor activity in breast cancer cells
Keenen MM, Kim S
Breast Cancer: Targets and Therapy 2016, 8:211-221
Published Date: 17 November 2016
Are another 5 years of adjuvant aromatase inhibitor therapy needed?
Mo QG, Li DQ, Zhong JH, Wei CY
Breast Cancer: Targets and Therapy 2016, 8:207-209
Published Date: 14 November 2016
Statins and risk of breast cancer recurrence
Sakellakis M, Akinosoglou K, Kostaki A, Spyropoulou D, Koutras A
Breast Cancer: Targets and Therapy 2016, 8:199-205
Published Date: 4 November 2016
Current advances in biomarkers for targeted therapy in triple-negative breast cancer
Fleisher B, Clarke C, Ait-Oudhia S
Breast Cancer: Targets and Therapy 2016, 8:183-197
Published Date: 6 October 2016
Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system
Rashid N, Koh HA, Baca HC, Lin KJ, Malecha SE, Masaquel A
Breast Cancer: Targets and Therapy 2016, 8:173-181
Published Date: 4 October 2016
Reducing infection risk in implant-based breast-reconstruction surgery: challenges and solutions
Ooi ASH, Song DH
Breast Cancer: Targets and Therapy 2016, 8:161-172
Published Date: 1 September 2016
Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about “Triple-negative breast cancer: treatment challenges and solutions” by Collignon et al
Ieni A, Barresi V, Ricciardi GRR, Adamo B, Adamo V, Tuccari G
Breast Cancer: Targets and Therapy 2016, 8:157-159
Published Date: 19 August 2016
Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment
Charoenchokthavee W, Panomvana D, Sriuranpong V, Areepium N
Breast Cancer: Targets and Therapy 2016, 8:149-155
Published Date: 8 August 2016
Adjuvant systemic therapy in older women with breast cancer
Leone J, Leone BA, Leone JP
Breast Cancer: Targets and Therapy 2016, 8:141-147
Published Date: 25 July 2016
A systematic review and meta-analysis of Harmonic technology compared with conventional techniques in mastectomy and breast-conserving surgery with lymphadenectomy for breast cancer
Cheng H, Clymer JW, Ferko NC, Patel L, Soleas IM, Cameron CG, Hinoul P
Breast Cancer: Targets and Therapy 2016, 8:125-140
Published Date: 18 July 2016
The absence of aldehyde dehydrogenase 1 A1-positive cells in benign mammary stroma is associated with risk factors for breast cancer
Isfoss BL, Holmqvist B, Jernström H, Alm P, Olsson H
Breast Cancer: Targets and Therapy 2016, 8:117-124
Published Date: 27 May 2016
Is radiation-induced ovarian ablation in breast cancer an obsolete procedure? Results of a meta-analysis
Al Asiri M, Tunio MA, Abdulmoniem R
Breast Cancer: Targets and Therapy 2016, 8:109-116
Published Date: 25 May 2016
Triple-negative breast cancer: treatment challenges and solutions
Collignon J, Lousberg L, Schroeder H, Jerusalem G
Breast Cancer: Targets and Therapy 2016, 8:93-107
Published Date: 20 May 2016
Profile of palbociclib in the treatment of metastatic breast cancer
Ehab M, Elbaz M
Breast Cancer: Targets and Therapy 2016, 8:83-91
Published Date: 17 May 2016
Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer
Yardley DA
Breast Cancer: Targets and Therapy 2016, 8:73-82
Published Date: 3 May 2016
Modulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH-015, is calcium dependent
Hanlon KE, Lozano-Ondoua AN, Umaretiya PJ, Symons-Liguori AM, Chandramouli A, Moy JK, Kwass WK, Mantyh PW, Nelson MA, Vanderah TW
Breast Cancer: Targets and Therapy 2016, 8:59-71
Published Date: 15 April 2016
Breast cancer characteristics in very young Egyptian women ≤35 years
Farouk O, Ebrahim MA, Senbel A, Emarah Z, Abozeed W, Seisa MO , Mackisack S, Abdel Jalil S, Abdelhady S
Breast Cancer: Targets and Therapy 2016, 8:53-58
Published Date: 5 April 2016
Factors affecting local recurrence and distant metastases of invasive breast cancer after breast-conserving surgery in Chiang Mai University Hospital
Ditsatham C, Somwangprasert A, Watcharachan K, Wongmaneerung P, Khorana J
Breast Cancer: Targets and Therapy 2016, 8:47-52
Published Date: 18 March 2016
Astym therapy improves function and range of motion following mastectomy
Davies CC, Brockopp D, Moe K
Breast Cancer: Targets and Therapy 2016, 8:39-45
Published Date: 8 March 2016
Identification and prioritization of candidate genes for symptom variability in breast cancer survivors based on disease characteristics at the cellular level
Koleck TA, Conley YP
Breast Cancer: Targets and Therapy 2016, 8:29-37
Published Date: 8 March 2016
Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer
Casneuf T, Axel AE, King P, Alvarez JD, Werbeck JL, Verhulst T, Verstraeten K, Hall BM, Sasser AK
Breast Cancer: Targets and Therapy 2016, 8:13-27
Published Date: 3 February 2016
Managing breast cancer in younger women: challenges and solutions
Ademuyiwa FO, Cyr A, Ivanovich J, Thomas MA
Breast Cancer: Targets and Therapy 2016, 8:1-12
Published Date: 21 December 2015
A GM-CSF and CD40L bystander vaccine is effective in a murine breast cancer model
Soliman H, Mediavilla-Varela M, Antonia SJ
Breast Cancer: Targets and Therapy 2015, 7:389-397
Published Date: 15 December 2015
Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators?
Chatterjee S, Saha A, Arun I, Nayak SS, Sinha S, Agrawal S, Parihar M, Ahmed R
Breast Cancer: Targets and Therapy 2015, 7:381-388
Published Date: 10 December 2015
Optimal delivery of male breast cancer follow-up care: improving outcomes
Ferzoco RM, Ruddy KJ
Breast Cancer: Targets and Therapy 2015, 7:371-379
Published Date: 23 November 2015
Hypofractionated whole breast radiotherapy: current perspectives
Koulis TA, Phan T, Olivotto IA
Breast Cancer: Targets and Therapy 2015, 7:363-370
Published Date: 27 October 2015
Exercise after breast cancer treatment: current perspectives
Dieli-Conwright CM, Orozco BZ
Breast Cancer: Targets and Therapy 2015, 7:353-362
Published Date: 21 October 2015
Symptom report in detecting breast cancer-related lymphedema
Fu MR, Axelrod D, Cleland CM, Qiu Z, Guth AA, Kleinman R, Scagliola J, Haber J
Breast Cancer: Targets and Therapy 2015, 7:345-352
Published Date: 15 October 2015
Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes
Martei YM, Matro JM
Breast Cancer: Targets and Therapy 2015, 7:337-343
Published Date: 8 October 2015
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer
Advani P, Cornell L, Chumsri S, Moreno-Aspitia A
Breast Cancer: Targets and Therapy 2015, 7:321-335
Published Date: 22 September 2015
The network of pluripotency, epithelial–mesenchymal transition, and prognosis of breast cancer
Voutsadakis IA
Breast Cancer: Targets and Therapy 2015, 7:303-319
Published Date: 7 September 2015
Taxanes in the elderly patient with metastatic breast cancer
Yardley DA
Breast Cancer: Targets and Therapy 2015, 7:293-301
Published Date: 3 September 2015
Are there efficacious treatments for treating the fatigue–sleep disturbance–depression symptom cluster in breast cancer patients? A Rapid Evidence Assessment of the Literature (REAL©)
Jain S, Boyd C, Fiorentino L, Khorsan R, Crawford C
Breast Cancer: Targets and Therapy 2015, 7:267-291
Published Date: 2 September 2015
Combined 2-deoxy glucose and metformin improves therapeutic efficacy of sodium-iodide symporter-mediated targeted radioiodine therapy in breast cancer cells
Chatterjee S, Thaker N, De A
Breast Cancer: Targets and Therapy 2015, 7:251-265
Published Date: 31 August 2015
Pathological response rate in hormone-positive breast cancer patients treated with neoadjuvant FEC and triweekly docetaxel: a case series
Kiba T, Morii N, Takahashi H, Ozaki S, Atsumi M, Masumoto F, Yamashiro H
Breast Cancer: Targets and Therapy 2015, 7:245-250
Published Date: 28 August 2015
Triple negative breast cancer: an Indian perspective
Akhtar M, Dasgupta S, Rangwala M
Breast Cancer: Targets and Therapy 2015, 7:239-243
Published Date: 14 August 2015
Molecular heterogeneity in adjacent cells in triple-negative breast cancer
Huebschman ML, Lane NL, Liu HY, Sarode VR, Devlin JL, Frenkel EP
Breast Cancer: Targets and Therapy 2015, 7:231-237
Published Date: 11 August 2015
Establishment and characterization of a receptor-negative, hormone-nonresponsive breast cancer cell line from an Iraqi patient
Al-Shammari AM, Alshami MA, Umran MA, Almukhtar AA, Yaseen NY, Raad K, Hussien AA
Breast Cancer: Targets and Therapy 2015, 7:223-230
Published Date: 7 August 2015
Accelerated partial breast irradiation with brachytherapy: patient selection and technique considerations
Trifiletti DM, Romano KD, Showalter SL, Reardon KA, Libby B, Showalter TN
Breast Cancer: Targets and Therapy 2015, 7:211-221
Published Date: 29 July 2015
Optical imaging for breast cancer prescreening
Godavarty A, Rodriguez S, Jung YJ, Gonzalez S
Breast Cancer: Targets and Therapy 2015, 7:193-209
Published Date: 20 July 2015
Identification of genes involved in breast cancer and breast cancer stem cells
Apostolou P, Toloudi M, Papasotiriou I
Breast Cancer: Targets and Therapy 2015, 7:183-191
Published Date: 15 July 2015
Importance of perforating vessels in nipple-sparing mastectomy: an anatomical description
Amanti C, Vitale V, Lombardi A, Maggi S, Bersigotti L, Lazzarin G, Nuccetelli E, Romano C, Campanella L, Cristiano L, Bartoloni A, Argento G
Breast Cancer: Targets and Therapy 2015, 7:179-181
Published Date: 14 July 2015
Safety and esthetic outcomes of therapeutic mammoplasty using medial pedicle for early breast cancer
Roshdy S, Hussein O, Khater A, Zuhdy M, El-Hadaad HA, Farouk O, Senbel A, Fathi A, Hamed E, Denewer A
Breast Cancer: Targets and Therapy 2015, 7:173-178
Published Date: 7 July 2015
Management of early breast cancer in older women: from screening to treatment
Elomrani F, Zine M, Afif M, L’annaz S, Ouziane I, Mrabti H, Errihani H
Breast Cancer: Targets and Therapy 2015, 7:165-171
Published Date: 7 July 2015
BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase [Corrigendum]
Larsen S, Butthongkomvong K, Manikhas A, Trishkina E, Poddubuskaya E, Matrosova M, Srimuninnimit V, Lindkær-Jensen S
Breast Cancer: Targets and Therapy 2015, 7:163-164
Published Date: 29 June 2015
Profile of neratinib and its potential in the treatment of breast cancer
Feldinger K, Kong A
Breast Cancer: Targets and Therapy 2015, 7:147-162
Published Date: 9 June 2015
Development and psychometric testing of a breast cancer patient-profiling questionnaire
Gorini A, Mazzocco K, Gandini S, Munzone E, McVie G, Pravettoni G
Breast Cancer: Targets and Therapy 2015, 7:133-146
Published Date: 1 June 2015
The expanding role of pertuzumab in the treatment of HER2-positive breast cancer
Moya-Horno I, Cortés J
Breast Cancer: Targets and Therapy 2015, 7:125-132
Published Date: 21 May 2015
PI3K mutations in breast cancer: prognostic and therapeutic implications
Mukohara T
Breast Cancer: Targets and Therapy 2015, 7:111-123
Published Date: 15 May 2015
Role of the WASP and WAVE family proteins in breast cancer invasion and metastasis
Frugtniet B, Jiang WG, Martin TA
Breast Cancer: Targets and Therapy 2015, 7:99-109
Published Date: 24 April 2015
Methods to improve rehabilitation of patients following breast cancer surgery: a review of systematic reviews
Loh SY, Musa AN
Breast Cancer: Targets and Therapy 2015, 7:81-98
Published Date: 11 March 2015
Critical analysis of the potential for microRNA biomarkers in breast cancer management
Graveel CR, Calderone HM, Westerhuis JJ, Winn ME, Sempere LF
Breast Cancer: Targets and Therapy 2015, 7:59-79
Published Date: 23 February 2015
Internalization: acute apoptosis of breast cancer cells using herceptin-immobilized gold nanoparticles
Rathinaraj P, Al-Jumaily AM, Huh DS
Breast Cancer: Targets and Therapy 2015, 7:51-58
Published Date: 10 February 2015
Breast cancer in Brazil: epidemiology and treatment challenges
Cecilio AP, Takakura ET, Jumes JJ, dos Santos JW, Herrera AC, Victorino VJ, Panis C
Breast Cancer: Targets and Therapy 2015, 7:43-49
Published Date: 29 January 2015
A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients
Aphinives P, Vachirodom D, Thanapaisal C, Rangsrikajee D, Somintara O
Breast Cancer: Targets and Therapy 2015, 7:37-41
Published Date: 20 January 2015
Cardiac risk in the treatment of breast cancer: assessment and management
Valachis A, Nilsson C
Breast Cancer: Targets and Therapy 2015, 7:21-35
Published Date: 16 January 2015
Epithelial-to-mesenchymal transition in breast cancer: a role for insulin-like growth factor I and insulin-like growth factor–binding protein 3?
Zielinska HA, Bahl A, Holly JMP, Perks CM
Breast Cancer: Targets and Therapy 2015, 7:9-19
Published Date: 19 January 2015
Factors associated with contralateral preventive mastectomy
Yakoub D, Avisar E, Koru-Sengul T, Miao F, Tannenbaum SL, Byrne MM, Moffat F, Livingstone A, Franceschi D
Breast Cancer: Targets and Therapy 2015, 7:1-8
Published Date: 7 January 2015
Immunohistochemical analysis of aldehyde dehydrogenase isoforms and their association with estrogen-receptor status and disease progression in breast cancer
Opdenaker LM, Arnold KM, Pohlig RT, Padmanabhan JS, Flynn DC, Sims-Mourtada J
Breast Cancer: Targets and Therapy 2014, 6:205-209
Published Date: 12 December 2014
Oseltamivir phosphate monotherapy ablates tumor neovascularization, growth, and metastasis in mouse model of human triple-negative breast adenocarcinoma
Haxho F, Allison S, Alghamdi F, Brodhagen L, Kuta VE, Abdulkhalek S, Neufeld RJ, Szewczuk MR
Breast Cancer: Targets and Therapy 2014, 6:191-203
Published Date: 9 December 2014
BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase
Larsen S, Butthongkomvong K, Manikhas A, Trishkina E, Poddubuskaya E, Matrosova M, Srimuninnimit V, Lindkær-Jensen S
Breast Cancer: Targets and Therapy 2014, 6:179-189
Published Date: 27 November 2014
Assessment of HER2 testing patterns, HER2+ disease, and the utilization of HER2-directed therapy in early breast cancer
Stenehjem DD, Yoo M, Unni SK, Singhal M, Bauer H, Saverno K, Quah C, Masaquel A, Brixner DI
Breast Cancer: Targets and Therapy 2014, 6:169-177
Published Date: 29 October 2014
Recent advances in the development of breast cancer vaccines
Milani A, Sangiolo D, Aglietta M, Valabrega G
Breast Cancer: Targets and Therapy 2014, 6:159-168
Published Date: 14 October 2014
Locoregional recurrence of triple-negative breast cancer: effect of type of surgery and adjuvant postoperative radiotherapy
Bayoumi Y, AbdelSamie A, Abdelsaid A, Radwan A
Breast Cancer: Targets and Therapy 2014, 6:151-158
Published Date: 10 September 2014
Effects of switching from anastrozole to letrozole, due to reimbursement policy, on the outcome of breast cancer therapy
Aphinives P, Vachirodom D, Thanapaisal C, Rangsrikajee D, Somintara O
Breast Cancer: Targets and Therapy 2014, 6:145-150
Published Date: 27 August 2014
Breast carcinomas: variations in sonoelastographic appearance
Fleury E, Assunção-Queiroz M, Roveda Jr D
Breast Cancer: Targets and Therapy 2014, 6:135-143
Published Date: 4 August 2014
Palbociclib: an evidence-based review of its potential in the treatment of breast cancer
Cadoo KA, Gucalp A, Traina TA
Breast Cancer: Targets and Therapy 2014, 6:123-133
Published Date: 4 August 2014
Barrier protective use of skin care to prevent chemotherapy-induced cutaneous symptoms and to maintain quality of life in patients with breast cancer
Wohlrab J, Bangemann N, Kleine-Tebbe A, Thill M, Kümmel S, Grischke EM, Richter R, Seite S, Lüftner D
Breast Cancer: Targets and Therapy 2014, 6:115-122
Published Date: 1 August 2014
Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
Oostra DR, Macrae ER
Breast Cancer: Targets and Therapy 2014, 6:103-113
Published Date: 23 July 2014
Preserving fertility in patients undergoing treatment for breast cancer: current perspectives
Moffat R, Güth U
Breast Cancer: Targets and Therapy 2014, 6:93-101
Published Date: 17 July 2014
Candidate prognostic markers in breast cancer: focus on extracellular proteases and their inhibitors
Roy DM, Walsh LA
Breast Cancer: Targets and Therapy 2014, 6:81-91
Published Date: 3 July 2014
The role of peroxiredoxin II in chemoresistance of breast cancer cells
Wang T, Diaz AJG, Yen Y
Breast Cancer: Targets and Therapy 2014, 6:73-80
Published Date: 23 May 2014
Current strategies for the prevention of breast cancer
Advani P, Moreno-Aspitia A
Breast Cancer: Targets and Therapy 2014, 6:59-71
Published Date: 2 May 2014
Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes
Jerusalem G, Rorive A, Collignon J
Breast Cancer: Targets and Therapy 2014, 6:43-57
Published Date: 17 April 2014
Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
Sawaki M
Breast Cancer: Targets and Therapy 2014, 6:37-41
Published Date: 15 April 2014
Tamoxifen for women at high risk of breast cancer
Nazarali SA, Narod SA
Breast Cancer: Targets and Therapy 2014, 6:29-36
Published Date: 17 February 2014
Emerging role of cell polarity proteins in breast cancer progression and metastasis
Chatterjee SJ, McCaffrey L
Breast Cancer: Targets and Therapy 2014, 6:15-27
Published Date: 9 January 2014
Multidrug-resistant breast cancer: current perspectives
Martin HL, Smith L, Tomlinson DC
Breast Cancer: Targets and Therapy 2014, 6:1-13
Published Date: 10 January 2014
Breast cancer causes and treatment: where are we going wrong?
Seymour CB, Mothersill C
Breast Cancer: Targets and Therapy 2013, 5:111-119
Published Date: 3 December 2013
The incidence rate of female breast cancer in Saudi Arabia: an observational descriptive epidemiological analysis of data from Saudi Cancer Registry 2001–2008
Alghamdi IG, Hussain II, Alghamdi MS, El-Sheemy MA
Breast Cancer: Targets and Therapy 2013, 5:103-109
Published Date: 17 October 2013
Enhanced radiation response in radioresistant MCF-7 cells by targeting peroxiredoxin II
Diaz AJG, Tamae D, Yen Y, Li JJ, Wang T
Breast Cancer: Targets and Therapy 2013, 5:87-101
Published Date: 11 October 2013
Benefits of multidisciplinary teamwork in the management of breast cancer
Taylor C, Shewbridge A, Harris J, Green JS
Breast Cancer: Targets and Therapy 2013, 5:79-85
Published Date: 30 August 2013
Effects of CYP2D6 and UGT2B7 polymorphisms on pharmacokinetics of tamoxifen in Thai breast cancer patients
Areepium N, Panomvana D, Rungwanonchai P, Sathaporn S, Voravud N
Breast Cancer: Targets and Therapy 2013, 5:73-78
Published Date: 22 August 2013
Emerging targeted combinations in the management of breast cancer
Lee RJ, Armstrong AC, Wardley AM
Breast Cancer: Targets and Therapy 2013, 5:61-72
Published Date: 13 August 2013
Elevated preoperative serum cancer antigen 15.3 levels are associated with reduced disease-free survival: a single-institution experience
Alsaeed EF, Abdulkarim H, Tunio MA
Breast Cancer: Targets and Therapy 2013, 5:53-59
Published Date: 26 July 2013
Contribution of toll-like receptor signaling pathways to breast tumorigenesis and treatment
Kidd LR, Rogers EN, Yeyeodu ST, Jones DZ, Kimbro KS
Breast Cancer: Targets and Therapy 2013, 5:43-51
Published Date: 28 June 2013
Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel versus carboplatin/docetaxel in initial treatment of metastatic Her-2-negative breast cancer
Abdel Kader Y, Spielmann M, El-Nahas T, Sakr A, Metwally H
Breast Cancer: Targets and Therapy 2013, 5:37-42
Published Date: 17 June 2013
Clinical evidence of the efficacy of everolimus and its potential in the treatment of breast cancer
Saksena R, Wong ST
Breast Cancer: Targets and Therapy 2013, 5:27-35
Published Date: 17 May 2013
Population-based service mammography screening: the Icelandic experience
Sigurdsson K, Ólafsdóttir EJ
Breast Cancer: Targets and Therapy 2013, 5:17-25
Published Date: 9 May 2013
Patients opting for breast reconstruction following mastectomy: an analysis of uptake rates and benefit
Howard-McNatt MM
Breast Cancer: Targets and Therapy 2013, 5:9-15
Published Date: 25 February 2013
Serum calcium levels, TRPM7, TRPC1, microcalcifications, and breast cancer using breast imaging reporting and data system scores
Mandavilli S, Singh BB, Sahmoun AE
Breast Cancer: Targets and Therapy 2013, 5:1-7
Published Date: 28 December 2012
Implications for breast cancer dormancy in other areas of medicine
Rameshwar P
Breast Cancer: Targets and Therapy 2012, 4:193-195
Published Date: 5 December 2012
Dormancy in breast cancer
Banys M, Hartkopf AD, Krawczyk N, Kaiser T, Meier-Stiegen F, Fehm T, Neubauer H
Breast Cancer: Targets and Therapy 2012, 4:183-191
Published Date: 5 December 2012
Lapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective
Machado M, Einarson TR
Breast Cancer: Targets and Therapy 2012, 4:173-182
Published Date: 13 November 2012
Therapeutic reduction mammoplasty in large-breasted women with cancer using superior and superomedial pedicles
Denewer A, Shahatto F, Elnahas W, Farouk O, Roshdy S, Khater A, Hussein O, Teima S, Hafez M, Zidan S, Shams N, Kotb S
Breast Cancer: Targets and Therapy 2012, 4:167-172
Published Date: 25 October 2012
Keeping an open mind: highlights and controversies of the breast cancer stem cell theory
Shah M, Allegrucci C
Breast Cancer: Targets and Therapy 2012, 4:155-166
Published Date: 26 October 2012
Current and emerging quantitative magnetic resonance imaging methods for assessing and predicting the response of breast cancer to neoadjuvant therapy
Abramson RG, Arlinghaus LR, Weis JA, Li X, Dula AN, Chekmenev EY, Smith SA, Miga MI, Abramson VG, Yankeelov TE
Breast Cancer: Targets and Therapy 2012, 4:139-154
Published Date: 11 October 2012
Potential of afatinib in the treatment of patients with HER2-positive breast cancer
Geuna E, Montemurro F, Aglietta M, Valabrega G
Breast Cancer: Targets and Therapy 2012, 4:131-137
Published Date: 27 August 2012
Five-year follow-up of treatment outcomes in patients with early-stage breast cancer and clinically negative axillary nodes treated with no lymph node dissection or axillary clearance
Yamamoto D, Tanaka K, Tsubota Y, Sueoka N, Shoji T, Kuwana K, Kwon AH
Breast Cancer: Targets and Therapy 2012, 4:125-129
Published Date: 27 August 2012
Sonomammographic characteristics of invasive lobular carcinoma
Kombar OR, Fahmy DM, Brown MV, Farouk O, El-Damshety O
Breast Cancer: Targets and Therapy 2012, 4:115-124
Published Date: 30 July 2012
Wortmannin induces MCF-7 breast cancer cell death via the apoptotic pathway, involving chromatin condensation, generation of reactive oxygen species, and membrane blebbing
Akter R, Hossain MZ, Kleve MG, Gealt MA
Breast Cancer: Targets and Therapy 2012, 4:103-113
Published Date: 13 July 2012
Aromatase inhibitor-associated bone loss and its management with bisphosphonates in patients with breast cancer
Bauer M, Bryce J, Hadji P
Breast Cancer: Targets and Therapy 2012, 4:91-101
Published Date: 20 June 2012
Targeting γ-secretase in breast cancer
Han J, Shen Q
Breast Cancer: Targets and Therapy 2012, 4:83-90
Published Date: 21 June 2012
Decreased risk of breast cancer associated with oral bisphosphonate therapy
Mathew A, Brufsky A
Breast Cancer: Targets and Therapy 2012, 4:75-81
Published Date: 23 May 2012
Role of pertuzumab in the treatment of HER2-positive breast cancer
Hubalek M, Brantner C, Marth C
Breast Cancer: Targets and Therapy 2012, 4:65-73
Published Date: 28 May 2012
New developments in the treatment of HER2-positive breast cancer
Nahta R
Breast Cancer: Targets and Therapy 2012, 4:53-64
Published Date: 7 May 2012
Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer
Hurvitz SA, Kakkar R
Breast Cancer: Targets and Therapy 2012, 4:35-51
Published Date: 3 April 2012
Retraction
Singhai R
Breast Cancer: Targets and Therapy 2012, 4:33-34
Published Date: 8 March 2012
Psychiatric morbidity among Egyptian breast cancer patients and their partners and its impact on surgical decision-making
El-Hadidy MA, Elnahas W, Hegazy MAF, Hafez MT, Refky B, Abdel Wahab KM
Breast Cancer: Targets and Therapy 2012, 4:25-32
Published Date: 6 March 2012
A triple negative breast cancer: what it is not!
Katakkar SB
Breast Cancer: Targets and Therapy 2012, 4:21-23
Published Date: 24 February 2012
Potential clinical applications of halichondrins in breast cancer and other neoplasms
Ortega V, Cortes J
Breast Cancer: Targets and Therapy 2012, 4:9-19
Published Date: 8 February 2012
Radiotherapy of early breast cancer in scleroderma patients: our experience with four cases and a short review of the literature
Kyrgias G, Theodorou K, Zygogianni A, Tsanadis K, Zervoudis S, Tzitzikas, Koukourakis M
Breast Cancer: Targets and Therapy 2012, 4:3-8
Published Date: 24 January 2012
Corrigendum
Menis J, Twelves C
Breast Cancer: Targets and Therapy 2012, 4:1-2
Published Date: 30 December 2011
Does Veritas® play a role in breast reconstruction? a case report
Borgognone A, Anniboletti T, De Vita F
Breast Cancer: Targets and Therapy 2011, 3:175-177
Published Date: 20 December 2011
Invasive breast cancer in Argentine women: association between risk and prognostic factors with antigens of a peptidic and carbohydrate nature
Demichelis SO, Isla-Larrain MT, Cermignani L, Alberdi CG, Segal-Eiras A, Croce MV
Breast Cancer: Targets and Therapy 2011, 3:161-173
Published Date: 20 December 2011
Antiemetic therapy options for chemotherapy-induced nausea and vomiting in breast cancer patients
Chan VTC, Yeo W
Breast Cancer: Targets and Therapy 2011, 3:151-160
Published Date: 14 November 2011
Clinical utility of the combination of lapatinib and letrozole in the management of hormone receptor-positive and HER2-positive advanced breast cancer
Merriam PA, Sikov WM
Breast Cancer: Targets and Therapy 2011, 3:139-150
Published Date: 26 October 2011
Update on raloxifene: role in reducing the risk of invasive breast cancer in postmenopausal women
Vogel VG
Breast Cancer: Targets and Therapy 2011, 3:127-137
Published Date: 20 October 2011
Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update
Schneider RE, Barakat AY, Pippen JE, Osborne CR
Breast Cancer: Targets and Therapy 2011, 3:113-125
Published Date: 4 October 2011
Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer
Menis J, Twelves C
Breast Cancer: Targets and Therapy 2011, 3:101-111
Published Date: 26 August 2011
Breast reconstruction: current and future options
Paul Jr H, Prendergast TI, Nicholson B, White S, Frederick WA
Breast Cancer: Targets and Therapy 2011, 3:93-99
Published Date: 17 August 2011
Emerging role of brain metastases in the prognosis of breast cancer patients
Hambrecht A, Jandial R, Neman J
Breast Cancer: Targets and Therapy 2011, 3:79-91
Published Date: 10 August 2011
The p53 breast cancer tissue biomarker in Indian women
Patil V, Tayade M, Pingale S, Dalvi S, Rajekar R, Deshmukh H, Patil S, Singhai R
Breast Cancer: Targets and Therapy 2011, 3:71-78
Published Date: 11 August 2011
In vitro human skin permeation of endoxifen: potential for local transdermal therapy for primary prevention and carcinoma in situ of the breast
Lee O, Ivancic D, Chatterton RT Jr, Rademaker AW, Khan SA
Breast Cancer: Targets and Therapy 2011, 3:61-70
Published Date: 14 July 2011
Optimal management of bone metastases in breast cancer patients
Wong MH, Pavlakis N
Breast Cancer: Targets and Therapy 2011, 3:35-60
Published Date: 2 May 2011
Estrogen receptor (ER) and progesterone receptor (PgR) in breast cancer of Indian women
Patil AV, Bhamre RS, Singhai R, Tayade MB, Patil VW
Breast Cancer: Targets and Therapy 2011, 3:27-33
Published Date: 19 April 2011
Cancer biomarker HER-2/neu in breast cancer in Indian women
Singhai R, Patil VW, Patil AV
Breast Cancer: Targets and Therapy 2011, 3:21-26
Published Date: 29 March 2011
Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women
Vinayak W Patil, Rajeev Singhai, Amit V Patil, et al
Breast Cancer: Targets and Therapy 2011, 3:9-19
Published Date: 16 March 2011
Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer
Allan Lipton
Breast Cancer: Targets and Therapy 2011, 3:1-7
Published Date: 15 March 2011
Role of trastuzumab in the management of HER2-positive metastatic breast cancer
Andrea Milani, Filippo Montemurro, Luisa Gioeni, et al
Breast Cancer: Targets and Therapy 2010, 2:93-109
Published Date: 24 November 2010
Lapatinib: new opportunities for management of breast cancer
Julia Liao, Michelle Gallas, Mark Pegram, et al
Breast Cancer: Targets and Therapy 2010, 2:79-91
Published Date: 15 November 2010
Current and emerging treatment strategies for breast cancer-induced bone loss
Stephanie L Hines
Breast Cancer: Targets and Therapy 2010, 2:71-77
Published Date: 28 October 2010
Adjuvant treatment of breast cancer in postmenopausal women: role of exemestane
Iain RJ Macpherson, Colin Lindsay, Peter Canney
Breast Cancer: Targets and Therapy 2010, 2:59-70
Published Date: 14 October 2010
HER2-positive male breast cancer: an update
Laura Ottini, Carlo Capalbo, Piera Rizzolo, et al
Breast Cancer: Targets and Therapy 2010, 2:45-58
Published Date: 4 October 2010
Evidence for the role of bevacizumab in the treatment of advanced metastatic breast cancer: a review
Susan E Pories, Gerburg M Wulf
Breast Cancer: Targets and Therapy 2010, 2:37-44
Published Date: 21 June 2010
Progress in the development of a therapeutic vaccine for breast cancer
Andrew L Coveler, Nicole E Bates, Mary L Disis
Breast Cancer: Targets and Therapy 2010, 2:25-36
Published Date: 4 June 2010
Ixabepilone as monotherapy or in combination for the treatment of advanced breast cancer
Erin M Bertino, Bhuvaneswari Ramaswamy
Breast Cancer: Targets and Therapy 2010, 2:13-23
Published Date: 24 May 2010
Challenges in the development of future treatments for breast cancer stem cells
Shyam A Patel, Anicia Ndabahaliye, Philip K Lim, et al
Breast Cancer: Targets and Therapy 2010, 2:1-11
Published Date: 10 March 2010
p130Cas substrate domain signaling promotes migration, invasion, and survival of estrogen receptor-negative breast cancer cells
Anna C Cunningham-Edmondson, Steven K Hanks
Breast Cancer: Targets and Therapy 2009, 1:39-52
Published Date: 7 December 2009
EGFR may couple moderate alcohol consumption to increased breast cancer risk
Christopher P Mill, Julia A Chester, David J Riese II
Breast Cancer: Targets and Therapy 2009, 1:31-38
Published Date: 5 October 2009
Antiangiogenesis immunotherapy induces epitope spreading to Her-2/neu resulting in breast tumor immunoediting
Matthew M Seavey, Yvonne Paterson
Breast Cancer: Targets and Therapy 2009, 1:19-30
Published Date: 5 October 2009
New approaches in the management of advanced breast cancer – role of combination treatment with liposomal doxorubicin
Iain RJ Macpherson, TR Jeffry Evans
Breast Cancer: Targets and Therapy 2009, 1:1-18
Published Date: 31 August 2009